The BioPharm Brief: Smarter Targeting, Myeloid Engagers, Neuron Replacement

Jul 07, 06:32 PM
Headliner
Share
Subscribe

Today's BioPharm Brief explores three different ways biopharma companies are advancing precision medicine, from next generation bispecific antibody drug conjugates and myeloid engager immunotherapy to stem cell derived neuron replacement for Parkinson's disease.

Share
Subscribe
Next
The BioPharm Brief: Biomarkers, Bleeding, Breakthroughs
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: Cancer, Personalized
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief